Search Results - "De Bont, E."

Gene expression profiling in the leukemic stem cell-enriched CD34 fraction identifies target genes that predict prognosis in normal karyotype AML by de Jonge, H J M, Woolthuis, C M, Vos, A Z, Mulder, A, van den Berg, E, Kluin, P M, van der Weide, K, de Bont, E S J M, Huls, G, Vellenga, E, Schuringa, J J

“…In order to identify acute myeloid leukemia (AML) CD34 + -specific gene expression profiles, mononuclear cells from AML patients ( n =46) were sorted into CD34…”
Get full text

Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia by van Dijk, A D, Hoff, F W, Qiu, Y H, Chandra, J, Jabbour, E, de Bont, E S J M, Horton, T M, Kornblau, S M

“…Acute leukemia is an epigenetically heterogeneous disease. The intensity of treatment is currently guided by cytogenetic and molecular genetic risk…”
Get full text

Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML by Kampen, K R, ter Elst, A, Mahmud, H, Scherpen, F J G, Diks, S H, Peppelenbosch, M P, de Haas, V, Guryev, V, de Bont, E S J M

“…Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput…”
Get full text

Optimizing VAP scars after childhood cancer treatment: a pilot study by de Bruijn, C. M. A., Hoff, F. W., Bruggeman-Westermann, M. M., Terra, J. B., van Dijk, T. H., de Bont, E. S. J. M., Peek, A. M. L.

“…Purpose Majority of pediatric cancer patients are treated with chemotherapy using Venous Access Ports (VAP). However, after surgical removal of the VAP…”
Get full text

Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease by Miedema, K G E, Tissing, W J E, te Poele, E M, Kamps, W A, Alizadeh, B Z, Kerkhof, M, de Jongste, J C, Smit, H A, de Pagter, A P, Bierings, M, Boezen, H M, Postma, D S, de Bont, E S J M, Koppelman, G H

“…Little is known about the etiology of childhood acute lymphoblastic leukemia (ALL). The presence of atopic disease has been shown to protect against developing…”
Get full text

EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia by Balgobind, B V, Lugthart, S, Hollink, I H, Arentsen-Peters, S T J C M, van Wering, E R, de Graaf, S S N, Reinhardt, D, Creutzig, U, Kaspers, G J L, de Bont, E S J M, Stary, J, Trka, J, Zimmermann, M, Beverloo, H B, Pieters, R, Delwel, R, Zwaan, C M, van den Heuvel-Eibrink, M M

“…Overexpression of the ecotropic virus integration-1 ( EVI1 ) gene ( EVI1 +), localized at chromosome 3q26, is associated with adverse outcome in adult acute…”
Get full text

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation by Marshall, G M, Dalla Pozza, L, Sutton, R, Ng, A, de Groot-Kruseman, H A, van der Velden, V H, Venn, N C, van den Berg, H, de Bont, E S J M, Maarten Egeler, R, Hoogerbrugge, P M, Kaspers, G J L, Bierings, M B, van der Schoot, E, van Dongen, J, Law, T, Cross, S, Mueller, H, de Haas, V, Haber, M, Révész, T, Alvaro, F, Suppiah, R, Norris, M D, Pieters, R

“…Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome. In…”
Get full text

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation by MILLOT, F, GUILHOT, J, GUILHOT, F, SUTTORP, M, NELKEN, B, LEBLANC, T, DE BONT, E. S, BEKASSY, A. N, GADNER, H, SUFLIARSKA, S, STARY, J, GSCHJIDMEIER, H

“…A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia…”
Get full text

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System by Kampen, K R, Scherpen, F J G, Garcia-Manero, G, Yang, H, Kaspers, G J L, Cloos, J, Zwaan, C M, van den Heuvel-Eibrink, M M, Kornblau, S M, De Bont, E S J M

“…Loss of ephrin receptor (EphB1) expression may associate with aggressive cancer phenotypes; however, the mechanism of action remains unclear. To gain detailed…”
Get full text

Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? by Sie, M., De Bont, E. S. J. M., Scherpen, F. J. G., Hoving, E. W., Den Dunnen, W. F. A.

“…M. Sie, E. S. J. M. de Bont, F. J. G. Scherpen, E. W. Hoving and W. F. A. den Dunnen (2010) Neuropathology and Applied Neurobiology36, 636–647
Tumour…”
Get full text

Feasibility of video consultations in case of acute complications in children with haemophilia by Ludikhuize, L., Jansen, M. E., Hooimeijer, H. L., de Bont, E. S. J. M., Tamminga, R. Y. J.

Get full text

Association of polymorphisms in the TLR4 gene with the risk of developing neutropenia in children with leukemia by Miedema, K G E, te Poele, E M, Tissing, W J E, Postma, D S, Koppelman, G H, de Pagter, A P, Kamps, W A, Alizadeh, B Z, Boezen, H M, de Bont, E S J M

“…Infections are a major cause of morbidity and mortality in children with acute lymphoblastic leukemia (ALL). Susceptibility to infections increases as the…”
Get full text

The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia by Klein, G, Vellenga, E, Fraaije, M.W, Kamps, W.A, de Bont, E.S.J.M.

“…In the past decades, a lot of effort has been put in identifying the role of matrix metalloproteinases (MMPs) in cancer. The main role of MMPs in angiogenesis,…”
Get full text

Comparing visual and automated urine dipstick analysis in a general practice population by Cox, S M L, Hoitinga, P, Oudhuis, G J, Hopstaken, R M, Savelkoul, P H M, Cals, J W L, de Bont, E G P M

“…Urinary symptoms constitute the primary reason for female patients to consult their general practitioner. The urinary dipstick test serves as a cornerstone for…”
Get full text

High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome by Balgobind, B V, Zwaan, C M, Reinhardt, D, Arentsen-Peters, T J C M, Hollink, I H I M, de Haas, V, Kaspers, G J L, de Bont, E S J M, Baruchel, A, Stary, J, Meyer, C, Marschalek, R, Creutzig, U, den Boer, M L, Pieters, R, van den Heuvel-Eibrink, M M

“…Translocations involving the mixed lineage leukemia ( MLL ) gene, localized at 11q23, frequently occur in pediatric acute myeloid leukemia (AML). We recently…”
Get full text

Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells by Sikkema, A. H., de Bont, E. S. J. M., Molema, G., Dimberg, A., Zwiers, P. J., Diks, S. H., Hoving, E. W., Kamps, W. A., Peppelenbosch, M. P., den Dunnen, W. F. A.

“…A. H. Sikkema, E. S. J. M. de Bont, G. Molema, A. Dimberg, P. J. Zwiers, S. H. Diks, E. W. Hoving, W. A. Kamps, M. P. Peppelenbosch and W. F. A. den Dunnen…”
Get full text

Outcome after first relapse in children with acute lymphoblastic leukemia: A report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol by van den Berg, H., de Groot-Kruseman, H.A., Damen-Korbijn, C.M., de Bont, E.S.J.M, Schouten-van Meeteren, A.Y.N., Hoogerbrugge, P.M.

“…Background We report on the treatment of children and adolescents with acute lymphoblastic leukemia (ALL) in first relapse. The protocol focused on: (1)…”
Get full text

Cancer in adolescents and young adults in north Netherlands (1989–2003): increased incidence, stable survival and high incidence of second primary tumours by van Gaal, J. C., Bastiaannet, E., Schaapveld, M., Otter, R., Kluin-Nelemans, J. C., de Bont, E. S. J. M., van der Graaf, W. T. A.

“…Background: Lack of survival improvement in adolescents and young adults (AYA) with cancer has led to increased awareness of this young population. Design: We…”
Get full text

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling by Weidenaar, A C, ter Elst, A, Kampen, K R, Meeuwsen-de Boer, T G J, de Jonge, H J M, Scherpen, F J G, den Dunnen, W F A, Kamps, W A, de Bont, E S J M

“…Background: High vascular endothelial growth factor (VEGFA) levels at the time of diagnosis confer a worse prognosis to multiple malignancies. Our aim was to…”
Get full text

Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials by Kardos, G, Zwaan, C M, Kaspers, G J L, de-Graaf, S S N, de Bont, E S J M, Postma, A, Bökkerink, J P M, Weening, R S, van der Does-van den Berg, A, van Wering, E R, Korbijn, C, Hählen, K

“…This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols. A total of 303…”
Get full text